Atezolizumab in locally advanced or metastatic urothelial cancer : a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies
Sotelo, M. (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))
Alonso-Gordoa, Teresa (Hospital Universitario Ramón y Cajal (Madrid))
Gajate, Pablo (Hospital Universitario Ramón y Cajal (Madrid))
Gallardo, Eduard (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Morales-Barrera, R. (Hospital Universitari Vall d'Hebron)
Pérez-Gracia, J. L. (Clínica Universidad de Navarra)
Puente, J. (Hospital Clínico San Carlos (Madrid))
Sánchez, P.. (Roche Farma S.A. Medical Department)
Castellano, Daniel (Hospital Universitario 12 de Octubre (Madrid))
Durán, Ignacio (Instituto de Investigación Sanitaria Valdecilla (Santander, Cantàbria))
Universitat Autònoma de Barcelona

Data:	2021
Resum:	The studies IMvigor 210 cohort 2 and IMvigor211 evaluated the efficacy of atezolizumab in patients with locally advanced or metastatic urothelial cancer (mUC) upon progression to platinum-based chemotherapy worldwide. Yet, the real impact of this drug in specific geographical regions is unknown. We combined individual-level data from the 131 patients recruited in Spain from IMvigor210 cohort 2 and IMvigor211 in a pooled analysis. Efficacy and safety outcomes were assessed in the overall study population and according to PD-L1 expression on tumour-infiltrating immune cells. Full data were available for 127 patients; 74 (58%) received atezolizumab and 53 (42%) chemotherapy. Atezolizumab patients had a numerically superior median overall survival although not reaching statistical significance (9. 2 months vs 7. 7 months). No statistically significant differences between arms were observed in overall response rates (20. 3% vs 37. 0%) or progression-free survival (2. 1 months vs 5. 3 months). Nonetheless, median duration of response was superior for the immunotherapy arm (non-reached vs 6. 4 months; p = 0. 005). Additionally, among the responders, the 12-month survival rates seemed to favour atezolizumab (66. 7% vs 19. 9%). When efficacy was analyzed based on PD-L1 expression status, no significant differences were found. Treatment-related adverse events of any grade occurred more frequently in the chemotherapy arm [46/57 (81%) vs 44/74 (59%)]. Patients who achieved an objective response on atezolizumab presented a longer median duration of response and numerically superior 12 month survival rates when compared with chemotherapy responders along with a more favorable safety profile. PD-L1 expression did not discriminate patients who might benefit from atezolizumab.
Nota:	Funding: This study was funded by Roche Farma, Spain.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Estudi clínic ; recerca ; Versió publicada
Matèria:	Atezolizumab ; Metastatic urothelial cancer ; Duration of response ; Spain
Publicat a:	Clinical & Translational Oncology, Vol. 23 (2021) , p. 882-891, ISSN 1699-3055

DOI: 10.1007/s12094-020-02482-9
PMID: 32897497

10 p, 947.8 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d’Investigació i Innovació Parc Taulí (I3PT)
Articles > Articles de recerca
Articles > Articles publicats